Vepdegestrant
Brand names: Veppanu · Active ingredient: Vepdegestrant
In short: VEPPANU is indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least
What is Vepdegestrant used for?
VEPPANU is indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative,
estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.
Vepdegestrant dosage
Select patients for treatment of ER-positive, HER2-negative advanced or metastatic breast cancer with VEPPANU based on the presence of
ESR1 mutation(s) in plasma specimen using an FDA-authorized test
.
Information on FDA-authorized tests for detection of
ESR1 mutations in breast cancer is available at: http://www.fda.gov/CompanionDiagnostics.
The recommended dosage of VEPPANU is 200 mg taken orally once daily with food
until disease progression or unacceptable toxicity.
Swallow VEPPANU tablet(s) whole. Do not chew, crush, dissolve, or split prior to swallowing. Do not take VEPPANU tablets that are broken, cracked, or look damaged.
If a patient misses a dose or vomits after taking a dose, the patient should take the next dose at the regularly scheduled time.
The recommended dose reduction for adverse reactions is 100 mg orally once daily.
Permanently discontinue VEPPANU in patients who are unable to tolerate 100 mg orally once daily.
The recommended dosage modifications for VEPPANU for adverse reactions are provided in Table 1 and Table 2.
CTCAE Severity Grade | Dosage Modification
Abbreviations: CTCAE=National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events
Grade 1 | No dose modification is required.
Grade 2 | Consider interruption of VEPPANU until recovery to Grade ≤1 or baseline. Then resume VEPPANU at the same dose.
Grade 3 | First occurrence: Interrupt VEPPANU until recovery to Grade ≤1 or baseline. Then resume VEPPANU at the same dose or at the reduced dose at the discretion of the physician.
If the Grade 3 toxicity recurs, interrupt VEPPANU until recovery to Grade ≤1 or baseline. Then resume VEPPANU at the reduced dose or discontinue VEPPANU at the discretion of the physician.
Grade 4 | First occurrence: Interrupt VEPPANU until recovery to Grade ≤1 or baseline. Then resume VEPPANU at the reduced dose.
If a Grade 4 or intolerable adverse reaction recurs, permanently discontinue VEPPANU.
QTc Prolongation
Heart-rate corrected QTc using Fridericia's method.
| Dosage Modification and Management
QTc >480 ms or >60 ms increase from baseline
(and QTc ≤500 ms) | Withhold until QTc resolves to ≤480 ms and ≤60 ms above baseline, then resume VEPPANU at the same dose.
Identify and treat reversible causes (e.g., hypokalemia and hypomagnesemia).
Initiate more frequent ECG monitoring.
QTc >500 ms | Withhold until QTc resolves to ≤480 ms and ≤60 ms above baseline, then:
resume VEPPANU at the same dose if reversible cause is identified and corrected (e.g., hypokalemia and hypomagnesemia).
resume VEPPANU at the reduced dose if no reversible cause is identified.
Initiate more frequent ECG monitoring.
Permanently discontinue if QTc >500 ms recurs. …
How to take Vepdegestrant — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information).
QTc Interval Prolongation
Inform patients that VEPPANU can cause QTc interval prolongation, which may increase the risk of Torsade de Pointes, other ventricular arrhythmias, and sudden death. Advise patients or caregivers of the signs or symptoms associated with the clinical consequences of QTc interval prolongation and to seek immediate medical attention if these are suspected or develop. Instruct patients to consult with their healthcare provider prior to taking other drugs that cause QTc interval prolongation with VEPPANU
.
Embryo-Fetal Toxicity
Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females to inform their healthcare provider of a known or suspected pregnancy
.
Advise females of reproductive potential to use effective contraception during treatment with VEPPANU and for 2 weeks after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with VEPPANU and for 2 weeks after the last dose
. …
Warnings & precautions
Do not take this medicine if: None.
VEPPANU can cause QT (QTc) interval prolongation
.
In VERITAC-2, QTc interval prolongation was reported in 10% of patients; Grade 3 occurred in 1.6% of patients. The heart-rate corrected QTc interval using Fridericia's method was greater than 500 msec in 1.6% of patients, and the increase from baseline QTc was greater than 60 msec in 2.6% of patients. VEPPANU dose reduction was required for 0.3% of patients due to QTc interval prolongation
.
Correct electrolyte abnormalities, including hypokalemia and hypomagnesemia, prior to and during treatment with VEPPANU. Perform an ECG prior to initiation of treatment with VEPPANU, and do not initiate VEPPANU in patients with QTc > 470 msec. Repeat ECG approximately 4 weeks after initiating treatment and as clinically indicated. In patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval, additional ECG monitoring may be necessary. Avoid concomitant use of VEPPANU with strong CYP3A inhibitors or drugs known to prolong the QTc interval. Reduce VEPPANU dose when concomitant use with strong CYP3A inhibitors cannot be avoided
[see Dosage and Administration (2.4), Drug Interactions (7.1, 7.3), and Clinical Pharmacology (12.2)]. If concomitant use with other QTc-prolonging agents cannot be avoided, increase the frequency of ECG monitoring.
Withhold, reduce dose, or permanently discontinue based on severity
.
Based on findings from animal studies and its mechanism of action, VEPPANU can cause fetal harm when administered to a pregnant woman. …
Vepdegestrant side effects
The following clinically significant adverse reaction is described elsewhere in the labeling:
QTc Interval Prolongation
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of VEPPANU was evaluated in patients with ER-positive, HER2-negative, advanced or metastatic breast cancer following endocrine therapy in VERITAC-2 .
Patients received VEPPANU 200 mg orally once daily (N=312) or fulvestrant 500 mg intramuscularly on Days 1 and 15 of Cycle 1 and then on Day 1 of each subsequent 28-day cycle (N=307). Among patients who received VEPPANU, 33% were exposed for 6 months or longer and 6% were exposed for greater than one year.
Serious adverse reactions occurred in 9% of patients who received VEPPANU. The serious adverse reactions included any fracture (1.3%), fall, hypercalcemia, hepatic injury, pneumonia, musculoskeletal pain (0.6% each), and QTc prolonged (0.3%). Fatal adverse reactions occurred in 1.0% of patients who received VEPPANU, including dyspnea, cerebral ischemia, and unknown cause (one patient each).
Permanent discontinuation of VEPPANU due to an adverse reaction occurred in 2.9% of patients. Adverse reactions that resulted in permanent discontinuation of VEPPANU included increased alanine aminotransferase (ALT) and dyspnea (0.6% each). …
Drug interactions
Table 5 describes drug interactions where concomitant use of another drug affects VEPPANU.
Strong CYP3A Inhibitors
Prevention or Management | Strong CYP3A Inhibitors:
Avoid concomitant use of VEPPANU with strong CYP3A inhibitors in
patients receiving VEPPANU 200 mg once daily. If concomitant use cannot be avoided, reduce VEPPANU dosage .
Avoid concomitant use with strong CYP3A inhibitors in patients receiving VEPPANU 100 mg once daily.
Mechanism and Clinical Effect(s) | Vepdegestrant is a CYP3A substrate.
Concomitant use with a strong CYP3A inhibitor may increase
vepdegestrant plasma concentration , which may increase the risk of VEPPANU-associated adverse reactions.
Strong CYP3A Inducers
Prevention or Management | Avoid concomitant use with strong CYP3A inducers in patients receiving VEPPANU 200 mg once daily. If concomitant use cannot be avoided, increase VEPPANU dosage .
Avoid concomitant use with strong CYP3A inducers in patients receiving VEPPANU 100 mg once daily.
Mechanism and Clinical Effect(s) | Vepdegestrant is a CYP3A substrate.
Concomitant use with a strong CYP3A inducer may decrease vepdegestrant
plasma concentration , which may reduce the effectiveness of VEPPANU.
Table 6 describes drug interactions where concomitant use of VEPPANU affects another drug. …
About this medicine
Vepdegestrant is a heterobifunctional protein degrader. It is a small molecule comprised of an estrogen receptor binding domain joined by a linker to an E3 ligase binding domain. The chemical name of vepdegestrant is 2,6-piperidinedione, 3-[1,3-dihydro-1-oxo-5-[4-[[1-[4-[(1R,2S)-1,2,3,4-tetrahydro-6-hydroxy-2-phenyl-1-naphthalenyl]phenyl]-4-piperidinyl]methyl]-1-piperazinyl]-2H-isoindol-2-yl]-, (3S)-. The chemical structure of vepdegestrant is:
Vepdegestrant is white to off-white to pale yellow solid with the molecular formula of C45H49N5O4 and a molecular weight of 723.90 Daltons. Vepdegestrant solubility is pH dependent. The solubility ranges from freely soluble under gastric pH conditions to slightly soluble under intestinal pH conditions. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 484e21ba-8fe1-4c6d-b923-8ba4cf5b2f20. Read the full official label on DailyMed.
Related medicines
Levothyroxine Ergocalciferol Estradiol Ethinyl Estradiol and Norethindrone Alendronate Testosterone Thyroid Norethindrone